2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
65
Neoplasm Metastasis
6
Prostatic Neoplasms, Castration-Resistant
5
Non-metastatic Castration-resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
3
Neoplasms
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Hormone-sensitive Prostate Cancer
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Adenocarcinoma
2
Urogenital Diseases
1
Thrombocytosis
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-metastatic Prostate Cancer
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Interventions
Docetaxel
3
Androgen Antagonists
3
enzalutamide
2
darolutamide
2
apalutamide
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer
×
darolutamide
×
Clear all
NCT02799602
2025-12-04
ARASENS
Bayer
Phase 3
Completed
1,306 enrolled
25 charts
2 FDA
NCT06498921
2024-10-24
BELBEQA
Bayer
Completed
106 enrolled